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Invited Commentary
PROceedingWith the Patient-Reported Outcomes (PROs)
Version of the Common Terminology Criteria
for Adverse Events
BenjaminMovsas, MD
For more than 30 years, the standard process for reporting
toxicities in clinical oncology trials has been via the National
Cancer Institute’s (NCI’s)CommonTerminologyCriteria forAd-
verseEvents (CTCAE).Overall, this system,which includesap-
proximately 800 items, has
served our field well, such
that toxicities can be com-
pared across clinical trials
using a consistent language. Approximately 10% of the items
represent symptoms (eg, fatigue,nausea) that are currently re-
ported by clinicians. Prior studies, however, have shown that
there is often a disconnect, with substantial discrepancies
between patient and clinician reports of symptoms.1 This
begs the question: When it comes to reporting symptomatic
adverse events, should the perspective of the patient or the
clinician be primarily considered?
Somewouldargue that theclinician ismostqualified to re-
port symptomatic adverse events. After all, they have the
professional training and background to place the patient’s
symptoms into theoverall contextof thediseaseprocess.How-
ever, prior studieshavedemonstrated that, comparedwithpa-
tients, clinicians tend tounderreport the incidence and sever-
ityofpatients’ symptoms.1Quintenetal2provideevidence that
theaccuracyof clinician-basedCTCAEreportingwasenhanced
by addingpatient-reported outcomes (PROs) gleaneddirectly
from patients. At a fundamental level, how can anyone know
the patient’s subjective experience better than the patient?
Others may contend that PROs are not scientifically rig-
orous because they are based on subjective reporting. How-
ever,manyPRO instruments (such as theEuropeanOrganiza-
tion for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 [EORTCQLQ-C30] and the Functional
AssessmentofCancerTherapy)havebeen rigorously tested for
scientific validity and reliability.1 The fact is thatmuchPROre-
search is currently hypothesis driven and based on clinically
meaningful changesusingvalidated instruments.1Ontheother
hand, the CTCAE itself was developed empirically by expert
consensus but not evaluated for validity or reliability. In-
deed, limitations of the CTCAE as a psychometric instrument
to measure cancer symptom burden have previously been
described.2 In addition, PROs have often been shown to be
more powerful than standard prognosticators for predicting
survival in clinical oncology trials.1 Both the Food and Drug
Administration and NCI have adopted PROs in trials as the
benchmark for measuring subjective experiences.
In light of these considerations, the NCI decided to de-
velop a PRO measurement system as a companion to the
CTCAE, called the PRO-CTCAE. In the article by Dueck and
colleagues3 in this issueof JAMAOncology, theauthors tookon
the daunting task of analyzing the construct validity, reliabil-
ity, and responsiveness of the PRO-CTCAE system, which in-
cludes a library of 124 patient self-reporting items. This study
includedalmost 1000adultEnglish-speakingpatientswithcan-
cerundergoing chemotherapyand/or radiation therapy from9
US cancer centers and community oncology practices. Pa-
tients completed thePRO-CTCAE itemson tablet computersor
by telephone at 2 clinic visits, 1 to 6weeks apart, with a subset
1 day apart. The key comparators for validationwere the East-
ernCooperativeOncologyGroupperformancestatusandavali-
datedquality-of-life (QOL) instrument(EORTC-QLQ-C30).Over-
all, they demonstrated favorable validity, reliability, and
responsiveness of the PRO-CTCAE even in a rather diverse
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Dueck and colleagues3 deserve credit for validating such
a largenumberof individual symptomatic toxicity items insuch
adiverse groupofpatientswith cancer.Although this is an im-
portant first step,morework isneeded.For example, less than
4%of the patients in this study underwent cancer surgery, so
this group requires further study.As theauthorspointout, this
study included only English-speaking, US-residing patients
with cancer. Future studieswill need to focuson linguistic and
cultural adaptationsofPRO-CTCAEboth insideandoutside the
United States. The reliability data were limited to a subset of
items, such that further analysis of the test reliability will be
required. Practical issues will also need to be addressed re-
gardinghowPRO-CTCAEmayaffect administrative time, cost,
and patient burden over time. Beyond logistic issues, the ul-
timate successof thePRO-CTCAEwill dependon imparting its
importance and relevance to patients, clinicians, and other
stakeholders.
The PRO-CTCAE is exciting because it is a novel patient-
centered approach to adverse event (AE) reporting. By incor-
porating PROs into the AE reporting system, it provides a di-
rect and unbiased account of the patient experience that can
guide future treatment recommendations. This can provide a
more accurate summary of the patient’s treatment experi-
ence,whichwill be relevant for labelingdecisions and inform-
ing stakeholders and future users about the effects of treat-
ment. As Basch and colleagues4 have pointed out, a
fundamentalpremiseof thePRO-CTCAEproject is thatwhereas
clinicianshave theultimate responsibility forAE reporting re-
garding patient safety, patients are best able to describe their
ownexperiences.Thus,bothpatientsandcliniciansshouldplay
key roles in the reporting of symptomatic AEs.
In summary, the perspectives of the patients and the cli-
nicians are indeed both essential in that they each provide
valuable and complementary input, which, when integrated,
provides a more robust appreciation of patients’ symptoms.
Clinicians contribute their professional experience to this
evaluation, while patients directly communicate their sub-
jective experiences.4 The power of the PRO-CTCAE is that it
intertwines the patient perspective directly into the AE
reporting using a validated methodology that can facilitate
informed decision making. In the future, the PRO-CTCAE
may be used as a strategy to provide real-time information
about patients’ symptoms so that clinicians can enhance
their communication with patients regarding symptom
management. Importantly, randomized data have demon-
strated that when inquiries are made regarding PROs in the
clinic, not only did physician-patient communication sig-
nificantly improve, but almost all patients also expressed
interest in continuing this approach.5 One thing is reason-
ably clear: when it comes to optimally understanding and
appreciating the patient experience, our patients want us to
“PRO”ceed with PROs.
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